Rhythm Pharmaceuticals Inc Market Cap ($5.84 Billion)
Market Cap & Net Worth: Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals Inc market cap. Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) has a market capitalization of $5.84 Billion ($5.84 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3123 globally and #1124 in its home market, demonstrating a 1.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rhythm Pharmaceuticals Inc's stock price $92.57 by its total outstanding shares 68285039 (68.29 Million). Also see Rhythm Pharmaceuticals Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Rhythm Pharmaceuticals Inc Market Cap History (2017–2026)
Rhythm Pharmaceuticals Inc market cap history from 2017 to 2026. Data shows growth from $1.98 Billion to $6.32 Billion (13.22% CAGR). Check RYTM stock price and chart for real-time trading data and today's change.
Index Memberships
Rhythm Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.22% | #78 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.01% | #351 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.32% | #54 of 263 |
Weight: Rhythm Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rhythm Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rhythm Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore RYTM net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
38.52x
Rhythm Pharmaceuticals Inc's market cap is 38.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.03 Billion | $35.00K | -$130.73 Million | 58003.26x | N/A |
| 2021 | $681.48 Million | $3.15 Million | -$68.01 Million | 216.07x | N/A |
| 2022 | $1.99 Billion | $23.64 Million | -$181.12 Million | 84.12x | N/A |
| 2023 | $3.14 Billion | $77.43 Million | -$184.68 Million | 40.54x | N/A |
| 2024 | $3.82 Billion | $130.13 Million | -$260.60 Million | 29.38x | N/A |
| 2025 | $7.31 Billion | $189.76 Million | -$196.54 Million | 38.52x | N/A |
Competitor Companies of RYTM by Market Capitalization
Companies near Rhythm Pharmaceuticals Inc in the global market cap rankings as of November 1, 2026. Also see Rhythm Pharmaceuticals Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to Rhythm Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Rhythm Pharmaceuticals Inc (2017–2026)
Market capitalization of Rhythm Pharmaceuticals Inc from 2017 to today. Between 2017 and today, Rhythm Pharmaceuticals Inc's market cap moved from $1.98 Billion to $ 6.32 Billion, with a yearly change of 13.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.32 Billion | -13.52% |
| 2025 | $7.31 Billion | +91.21% |
| 2024 | $3.82 Billion | +21.78% |
| 2023 | $3.14 Billion | +57.86% |
| 2022 | $1.99 Billion | +191.78% |
| 2021 | $681.48 Million | -66.43% |
| 2020 | $2.03 Billion | +29.49% |
| 2019 | $1.57 Billion | -14.58% |
| 2018 | $1.84 Billion | -7.50% |
| 2017 | $1.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Rhythm Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.84 Billion USD |
| MoneyControl | $5.84 Billion USD |
| MarketWatch | $5.84 Billion USD |
| marketcap.company | $5.84 Billion USD |
| Reuters | $5.84 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more